Literature DB >> 9094972

Polo-like kinase, a novel marker for cellular proliferation.

J Yuan1, A Hörlin, B Hock, H J Stutte, H Rübsamen-Waigmann, K Strebhardt.   

Abstract

PLK (polo-like kinase) belongs to a family of serine/threonine kinases and represents the human counterpart of polo in Drosophila melanogaster and of CDC5 in Saccharomyces cerevisiae. It is strongly involved in spindle formation and chromosome segregation during mitosis. We have shown previously that PLK mRNA expression correlates with the mitotic activity of cells and the prognosis of lung cancer patients. In this report, the level of PLK protein was analyzed using immunohistochemical techniques. PLK protein was found expressed in the nuclei of tumor cells from lung and breast cancer as well as in several tumor cell lines. Furthermore, in peripheral lymphocytes treated with phytohemagglutinin, elevated proliferative activity of the cells correlated with the up-regulation of PLK protein expression. In contrast, in U937 and HL-60 cells after induction of differentiation with phorbol ester, PLK immunostaining disappeared under conditions of terminal differentiation. Most of the PLK protein was found in the nucleus of proliferating cells with diffuse but distinct staining also in the cytoplasm. Taken together, high levels of PLK protein are associated with cellular proliferation. Combined with other proliferative and oncogene markers, PLK may be useful for improved prediction of the clinical prognosis of cancer patients and for early cancer diagnosis. Due to its activity late in the cell cycle, it may be a target for cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9094972      PMCID: PMC1858156     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  21 in total

1.  DIURNAL FLUCTUATIONS IN THE NUMBERS OF DNA SYNTHESIZING NUCLEI IN VARIOUS MOUSE TISSUES.

Authors:  C PILGRIM; W ERB; W MAURER
Journal:  Nature       Date:  1963-08-31       Impact factor: 49.962

2.  Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer.

Authors:  G Wolf; R Elez; A Doermer; U Holtrich; H Ackermann; H J Stutte; H M Altmannsberger; H Rübsamen-Waigmann; K Strebhardt
Journal:  Oncogene       Date:  1997-02-06       Impact factor: 9.867

3.  Identification and functional characterization of the human and murine polo-like kinase (Plk) promoter.

Authors:  A Bräuninger; K Strebhardt; H Rübsamen-Waigmann
Journal:  Oncogene       Date:  1995-11-02       Impact factor: 9.867

4.  Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1. A comparison with proliferating cell nuclear antigen.

Authors:  I O Ng; J Na; E C Lai; S T Fan; M Ng
Journal:  Am J Clin Pathol       Date:  1995-09       Impact factor: 2.493

5.  Cell proliferation markers in predicting metastases in malignant melanoma.

Authors:  V B Reddy; P Gattuso; G Aranha; H J Carson
Journal:  J Cutan Pathol       Date:  1995-06       Impact factor: 1.587

6.  Proliferative activity and DNA index do not significantly predict survival in primary central nervous system lymphoma.

Authors:  R Aho; H Haapasalo; K Alanen; M Haltia; A Paetau; H Kalimo
Journal:  J Neuropathol Exp Neurol       Date:  1995-11       Impact factor: 3.685

7.  Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1.

Authors:  K S Lee; Y L Yuan; R Kuriyama; R L Erikson
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

8.  Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1.

Authors:  A A Keshgegian; A Cnaan
Journal:  Am J Clin Pathol       Date:  1995-07       Impact factor: 2.493

9.  Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors.

Authors:  W Weikel; C Brumm; C Wilkens; T Beck; P G Knapstein
Journal:  Cancer Detect Prev       Date:  1995

10.  Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2,p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma.

Authors:  X F Sun; J M Carstensen; O Stål; H Zhang; B Nordenskjöld
Journal:  Int J Cancer       Date:  1996-02-20       Impact factor: 7.396

View more
  32 in total

Review 1.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

2.  Bioorthogonal probes for polo-like kinase 1 imaging and quantification.

Authors:  Ghyslain Budin; Katherine S Yang; Thomas Reiner; Ralph Weissleder
Journal:  Angew Chem Int Ed Engl       Date:  2011-08-24       Impact factor: 15.336

Review 3.  Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.

Authors:  Ravichandran N Murugan; Jung-Eun Park; Eun-Hee Kim; Song Yub Shin; Chaejoon Cheong; Kyung S Lee; Jeong Kyu Bang
Journal:  Mol Cells       Date:  2011-07-29       Impact factor: 5.034

4.  Dronc caspase exerts a non-apoptotic function to restrain phospho-Numb-induced ectopic neuroblast formation in Drosophila.

Authors:  Yingshi Ouyang; Claudia Petritsch; Hong Wen; Lily Jan; Yuh Nung Jan; Bingwei Lu
Journal:  Development       Date:  2011-06       Impact factor: 6.868

5.  Increased human polo-like kinase-1 expression in gliomas.

Authors:  K Dietzmann; E Kirches; K Jachau; C Mawrin
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

6.  Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.

Authors:  Campbell McInnes; Kara Estes; Merissa Baxter; Zhengguan Yang; Doaa Boshra Farag; Paul Johnston; John S Lazo; Jianjun Wang; Michael D Wyatt
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

7.  Association of genetic variation in mitotic kinases with breast cancer risk.

Authors:  Xianshu Wang; Zachary S Fredericksen; Robert A Vierkant; Matthew L Kosel; V Shane Pankratz; James R Cerhan; Christina Justenhoven; Hiltrud Brauch; Janet E Olson; Fergus J Couch
Journal:  Breast Cancer Res Treat       Date:  2009-04-30       Impact factor: 4.872

8.  Polo-like kinase 1 is essential for early embryonic development and tumor suppression.

Authors:  Lin-Yu Lu; Jamie L Wood; Katherine Minter-Dykhouse; Lin Ye; Thomas L Saunders; Xiaochun Yu; Junjie Chen
Journal:  Mol Cell Biol       Date:  2008-09-15       Impact factor: 4.272

9.  Housekeeping genes in prostate tumorigenesis.

Authors:  Jinyoung Byun; Christopher J Logothetis; Ivan P Gorlov
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

Review 10.  From Plk1 to Plk5: functional evolution of polo-like kinases.

Authors:  Guillermo de Cárcer; Gerard Manning; Marcos Malumbres
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.